The abstract is read at the publisher; the summary is JClub's.
Low serine-glycine-one-carbon (SGOC) pathway activity in non-MYCN-amplified high-risk neuroblastoma cells is linked to stronger purine salvage dependence, especially under SHMT inhibition.
- Why it matters: MYCN amplification creates intrinsic SGOC differences, but how SGOC activity shapes purine metabolism and salvage vulnerability is unclear.
- What they did: The authors compared non-MYCN-amplified versus MYCN-amplified neuroblastoma cell lines, using SHMT inhibition under serine- and glycine-deprived conditions, stable-isotope tracing, and genetic depletion of APRT or HPRT1.
- The result: Non-MYCN-amplified cells showed lower serine-derived one-carbon input to de novo purine synthesis, higher basal hypoxanthine and adenine salvage, and greater adenylate pool preservation during SHMT inhibition; APRT/HPRT1 depletion preferentially impaired their proliferation, and SHMT inhibition increased purine salvage.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.